Ilan Oren
Vermögen: 4 Mio $ am 31.05.2026
Vermögen: 4 Mio $ am 31.05.2026
Ilan Oren currently works at Dexcel Pharma Technologies Ltd., as Co-Chief Executive Officer from 2019, Dexcel Ltd., as Co - CEO, Roivant Sciences Ltd., as Independent Chairman from 2023, Roivant Sciences, Inc., as Director, Clexio Biosciences Ltd., as Director from 2018, Kriya Therapeutics, Inc., as Director from 2020, and 8400 - The Health Network, as Director from 2019.
Mr. Oren also formerly worked at Cynapsus Therapeutics, Inc., as Independent Director from 2014 to 2016, Sio Gene Therapies, Inc., as Director from 2018 to 2020, Sio Gene Therapies, Inc., as Non-Executive Director from 2015 to 2017, and Montes Archimedes Acquisition Corp., as Independent Director.
Mr. Oren received his undergraduate degree from Harvard College.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 17.04.2026 | 120’229 ( 0.02% ) | 4 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ROIVANT SCIENCES LTD. | Vorsitzender | 13.03.2023 |
Dexcel Pharma Technologies Ltd.
Dexcel Pharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes generic pharmaceuticals products | Vorstandsvorsitzender | 01.11.2019 |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Direktor/Vorstandsmitglied | - |
Kriya Therapeutics, Inc.
Kriya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing gene therapies for treatment of chronic diseases | Direktor/Vorstandsmitglied | 01.01.2020 |
Clexio Biosciences Ltd.
Clexio Biosciences Ltd. Pharmaceuticals: OtherHealth Technology Develops novel therapies for patients suffering from neurological and psychiatric conditions | Direktor/Vorstandsmitglied | 01.01.2018 |
8400 - The Health Network | Direktor/Vorstandsmitglied | 01.01.2019 |
Dexcel Ltd.
Dexcel Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets generic pharmaceuticals | Private Equity Investor | - |
| Unternehmen | Position | Ende |
|---|---|---|
| SIO GENE THERAPIES INC. | Direktor/Vorstandsmitglied | 24.09.2020 |
| SIO GENE THERAPIES INC. | Direktor/Vorstandsmitglied | 21.12.2017 |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Cynapsus Therapeutics, Inc.
Cynapsus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs | Health Technology |
Roivant Sciences Ltd.
Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | Health Technology |
Dexcel Ltd.
Dexcel Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets generic pharmaceuticals | Health Technology |
Dexcel Pharma Technologies Ltd.
Dexcel Pharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes generic pharmaceuticals products | Health Technology |
Harvard College
Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sio Gene Therapies, Inc.
Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops gene therapies to treat neurodegenerative diseases | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Clexio Biosciences Ltd.
Clexio Biosciences Ltd. Pharmaceuticals: OtherHealth Technology Develops novel therapies for patients suffering from neurological and psychiatric conditions | Health Technology |
Kriya Therapeutics, Inc.
Kriya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing gene therapies for treatment of chronic diseases | Health Technology |
Montes Archimedes Acquisition Corp.
Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
8400 - The Health Network | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen